These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2656617)

  • 41. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of resistance to ceftazidime during therapy for Enterobacter cloacae infections.
    Quinn JP; DiVincenzo CA; Foster J
    J Infect Dis; 1987 May; 155(5):942-7. PubMed ID: 3549922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital.
    Bamberger DM; Dahl SL
    Arch Intern Med; 1992 Mar; 152(3):554-7. PubMed ID: 1546918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Experimental Enterobacter cloacae endocarditis treated with gentamicin. Predictive value of the in vitro bactericidal rate].
    Potel G; Caillon J; Bugnon D; Lecomte P; Drugeon HB; Baron D
    Pathol Biol (Paris); 1988 May; 36(5):536-9. PubMed ID: 3043353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetics of a new cephalosporin, cefoperazone].
    Allaz AF; Dayer P; Fabre J; Rudhardt M; Balant L
    Schweiz Med Wochenschr; 1979 Dec; 109(50):1999-2005. PubMed ID: 538442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefepime clinical pharmacokinetics.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A
    Clin Pharmacokinet; 1993 Aug; 25(2):88-102. PubMed ID: 8403741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Progress in antibacterial chemotherapy].
    Naumann P; Rosin H
    Internist (Berl); 1978 Dec; 19(12):664-71. PubMed ID: 370047
    [No Abstract]   [Full Text] [Related]  

  • 48. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
    Sader HS; Castanheira M; Duncan LR; Flamm RK
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Laboratory and clinical studies on ceftazidime in the field of pediatrics].
    Kuno K; Yafuso M; Miyachi Y; Nakashima T; Ichihara K; Ueda S
    Jpn J Antibiot; 1984 Mar; 37(3):469-84. PubMed ID: 6376856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia.
    Geletko SM; Melbourne KM; Mikolich DJ
    Ann Pharmacother; 1996 Mar; 30(3):246-8. PubMed ID: 8833559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple beta-lactam resistance in Enterobacter cloacae following ceftazidime monotherapy.
    Black AS; Cohen J
    Lancet; 1985 Aug; 2(8450):331-2. PubMed ID: 2862496
    [No Abstract]   [Full Text] [Related]  

  • 53. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Wakai Y; Kamimura T; Tawara S; Matsumoto S; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):88-98. PubMed ID: 8436563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
    Tsuchimori N; Yamazaki T; Okonogi K
    J Antimicrob Chemother; 1997 Mar; 39(3):423-5. PubMed ID: 9096195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [In vitro activity of a new cephalosporin--cefoperazone--against Enterobacteriaceae and Pseudomonas aeruginosa].
    Modde H
    Schweiz Med Wochenschr; 1981 Mar; 111(10):356-8. PubMed ID: 6452690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice.
    Fu KP; Hetzel N; Hung PP; Gregory FJ
    J Antimicrob Chemother; 1986 Apr; 17(4):499-503. PubMed ID: 3710958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
    Blaser J; Bauernfeind A; Vogt M; Lüthy R
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1312-7. PubMed ID: 6411442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
    Fu KP; Vince T; McCloud S; Gregory FJ; Chiang ST; Hung PP
    Drugs Exp Clin Res; 1985; 11(11):787-91. PubMed ID: 3939215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    Int J Antimicrob Agents; 2004 Sep; 24(3):219-25. PubMed ID: 15325424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.